Early breast cancer in the older woman

Oncologist

Volumn 16, Issue 4, 2011, Pages 479-485

  Gandhi, Sonal ^a   Verma, Sunil ^a  

^a DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

Author keywords

Adjuvant chemotherapy; Adjuvant radiation; Aged; Breast neoplasms; General surgery; Geriatrics

Indexed keywords

ANTHRACYCLINE DERIVATIVE; AROMATASE INHIBITOR; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; METHOTREXATE; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB;

AGE; AGED; ARTHRALGIA; ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; COMORBIDITY; DISEASE FREE SURVIVAL; EARLY CANCER; ENDOMETRIUM CANCER; FEBRILE NEUTROPENIA; FOLLOW UP; HEART FAILURE; HUMAN; LYMPH NODE METASTASIS; LYMPHEDEMA; MAMMOGRAPHY; MENOPAUSAL SYNDROME; OSTEOPOROSIS; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PATIENT SELECTION; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SURVIVAL TIME; THROMBOEMBOLISM;

AGED; AGED, 80 AND OVER; AGING; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COMORBIDITY; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; RADIOTHERAPY, ADJUVANT; RISK FACTORS;

EID: 79955560616     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2010-0279     Document Type: Article

References (55)

1. Canadian Cancer Society. Canadian Cancer Statistics 2009. Available at http://www.cancer.ca/Canada-wide/About%20cancer/Types%20of%20cancer/Causes%20of%20breast%20cancer.aspx?sc_lang_en, accessed January 5, 2010.
2. SEER database. SEER Stat Fact Sheets: Breast. Available http://seer.cancer.gov/statfacts/html/breast.html, accessed January 6, 2010.
3. Hutchins LF, Unger JM, Crowley JJ et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999;341:2061-2067.
4. Reed MWR, Audisio RA, Wyld L. The role of surgery in the treatment of older women with breast cancer. Clin Oncol (R Coll Radiol) 2009;21:103-110.
5. Wildiers H, Kunkler I, Biganzoli L et al. Management of breast cancer in elderly individuals: Recommendations of the International Society of Geriatric Oncology. Lancet Oncol 2007;8:1101-1115.
6. Galit W, Green MS, Lital KB. Routine screening mammography in women older than 74 years: A review of the available data. Maturitas 2007;57:109-119.
7. Durbecq V, Ameye L, Veys I et al. A significant proportion of elderly patients develop hormone-dependant "luminal-B" tumours associated with aggressive characteristics. Crit Rev Oncol Hematol 2008;67:80-92.
8. Holmes CE, Muss HB. Diagnosis and treatment of breast cancer in the elderly. CA Cancer J Clin 2003;53:227-244.
9. Sardanelli F, Podo F, Santoro F et al. Multicenter surveillance of women at high genetic breast cancer risk using mammography, ultrasonography, and contrast-enhanced magnetic resonance imaging (the High Breast Cancer Risk Italian 1 Study): Final results. Invest Radiol 2011;46:94-105.
10. Laki F, Kirova YM, Savignoni A et al. Management of operable invasive breast cancer in women over the age of 70: long-term results of a large-scale singleinstitution experience. Ann Surg Oncol 2010;17:1530-1538.
11. Hind D, Wyld L, Beverley C et al. Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus). Cochrane Database Syst Rev 2006;(1):CD004272.
12. Reed MWR, Wyld L, Ellis P et al. Breast cancer in older women: Trials and tribulations. Clin Oncol (R Coll Radiol) 2009;21:99-102.
13. Albrand G, Terret C. Early breast cancer in the elderly: assessment and management considerations. Drugs Aging 2008;25:35-45.
14. Norman SA, Localio AR, Potashnik SL et al. Lymphedema in breast cancer survivors: Incidence, degree, time course, treatment, and symptoms. J Clin Oncol 2009;27:390-397.
15. Martelli G, Boracchi P, De Palo M et al. Arandomized trial comparing axillary dissection to no axillary dissection in older patients with T1N0 breast cancer: Results after 5 years of follow-up. Ann Surg 2005;242:1-6; discussion 7-9.
16. Truong PT, Bernstein V, Lesperance M et al. Radiotherapy omission after breast-conserving surgery is associated with reduced breast cancer-specific survival in elderly women with breast cancer. Am J Surg 2006;191:749-755.
17. Clarke M, Collins R, Darby S et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005;366:2087-2106.
18. Wildiers H. Challenges in treating older cancer patients: breast cancer. Ann Oncol 2008;19(suppl 7):vii99 -vii103.
19. Huguenin P, Glanzmann C, Lutolf UM. Acute toxicity of curative radiotherapy in elderly patients. Strahlenther Onkol 1996;172:658-663.
20. Wyckoff J, Greenberg H, Sanderson R et al. Breast irradiation in the older woman: A toxicity study. J Am Geriatr Soc 1994;42:150-152.
21. Valassiadou K, Morgan DA, Robertson JF et al. Successful management of elderly breast cancer patients treated without radiotherapy. World J Surg Oncol 2007;5:62.
22. Hughes KS, Schnaper LA, Cirrincione C et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 or older with early breast cancer. J Clin Oncol 2010;28(15 suppl):Abstract 507.
23. Kunkler IH, Williams LJ, King CC et al. Breast radiotherapy: Considerations in older patients. Clin Oncol (R Coll Radiol) 2009;21:111-117.
24. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005; 365:1687-1717.
25. Chlebowski R, Cuzick J, Amakye D et al. Clinical perspectives on the utility of aromatase inhibitors for the adjuvant treatment of breast cancer. Breast 2009; 18(suppl 2):S1-S11.
26. Iwase H. Current topics and perspectives on the use of aromatase inhibitors in the treatment of breast cancer. Breast Cancer 2008;15:278-290.
27. Tipples K, Robinson A. Optimising care of elderly breast cancer patients:A challenging priority. Clin Oncol (R Coll Radiol) 2009;2:118-130.
28. Braithwaite RS, Chlebowski RT, Lau J et al. Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med 2003;18:937-947.
29. Cuppone F, Bria E, Verma S et al. Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer? Meta-analysis of randomized trials. Cancer 2007;112:260-267.
30. Singh MS, Francis PA, Michael M. Tamoxifen, cytochrome P450 genes and breast cancer clinical outcomes. Breast 2010 Dec 23 [Epub ahead of print].
31. Rae JM, Drury S, Hayes DF et al. Lack of Correlation Between Gene Variants in Tamoxifen Metabolizing Enzymes with Primary Endpoints in the ATAC Trial. Presented at the San Antonio Breast Symposium, San Antonio, Texas, December 9, 2010. Available at http://www.abstracts2view.com/sabcs10/view.php?nu_SABCS10L_1093, accessed January 20, 2011.
32. Zaman K, Dahmane E, Csajka C et al. Prospective Assessment of CYP2D6 by Genotyping, Phenotyping and Measurement of Tamoxifen, 4-Hydroxy-Tamoxifen and Endoxifen in Breast Cancer Patients Treated with Tamoxifen. Presented at the San Antonio Breast Cancer Symposium, San Antonio, Texas, December 10, 2010. http://www.abstracts2view.com/sabcs10/view.php?nu_SABCS10L_1285, accessed January 20, 2011.
33. Hadji P, Body JJ, Aapro MS et al. Practical guidance for the management of aromatase inhibitor-associated bone loss. Ann Oncol 2008;19:1407-1416.
34. Goldhirsch A, Wood WC, Gelber RD et al. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007;18:1133-1144.
35. Muss HB, Berry DA, Cirrincione CT et al. Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med 2009;360:2055-2065.
36. Jones SE, Savin MA, Holmes FA et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 2006;24:5381-5387.
37. Jones S, Holmes F, O'Shaughnessy J et al. Extended follow-up and analysis by age of the US Oncology Adjuvant trial 9735: docetaxel/cyclophosphamide is associated with an overall survival benefit compared to doxorubicin/cyclophosphamide and is well-tolerated in women 65 or older. Breast Cancer Res Treat 2007;106(suppl 1):S5.
38. Perez EA, Suman VJ, Davidson NE et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol 2008;26:1231-1238.
39. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trials. Cancer 2003;97: 2869-2879.
40. Slamon D, Eiermann W, Robert N et al. BCIRG 006 Phase III Trial Comparing AC3T with AC3TH and with TCH in the Adjuvant Treatment of HER2- Amplified Early Breast Cancer Patients: Third Planned Efficacy Analysis. Presented at the 32nd Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, December 9-13, 2009.
41. Sawaki M, Iwata H, Kashiwaba M et al. Evaluation of Trastuzumab Without Chemotherapy as a Postoperative Adjuvant Therapy in HER2-Positive Elderly Breast Cancer Patients: Randomized Controlled Trial (RESPECT [N-SAS BC07]). Presented at the American Society of Clinical Oncology Annual Breast Cancer Symposium, Washington, D.C., October 1-3, 2010. Available at http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview_abst_detail_view&confID_100&abstractID_60159, accessed January 20, 2011.
42. Smith RE, Bryant J, DeCillis A et al. Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: The National Surgical Adjuvant Breast and Bowel Project Experience. J Clin Oncol 2003;21:1195-1204.
43. Schaapveld M, Visser O, Louwman MJ et al. Risk of new primary nonbreast cancers after breast cancer treatment: A Dutch population-based study. J Clin Oncol 2008;26:1239-1246.
44. Baxter NN, Durham SB, Phillips KA et al. Risk of dementia in older breast cancer survivors: A population-based cohort study of the association with adjuvant chemotherapy. J Am Geratr Soc 2009;57:403-411.
45. Schagen SB, van Dam FS, Muller MJ et al. Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer 1999;85:640-650.
46. Vardy J, Rourke S, Tannock IF. Evaluation of cognitive function associated with chemotherapy: A review of published studies and recommendations for future research. J Clin Oncol 2007;25:2455-2463.
47. Aapro M, Monfardini S, Jirillo A et al. Management of primary and advanced breast cancer in older unfit patients (medical treatment). Cancer Treat Rev 2009;35:503-508.
48. Marinello R, Marenco D, Roglia D et al. Predictors of treatment failures during chemotherapy: A prospective study on 110 older cancer patients. Arch Gerontol Geriatr 2009:48;222-226.
49. Paik S, Tang G, Shak S et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006;24:3726-3734.
50. van de Vijver MJ, He YD, van't Veer LJ et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999-2009.
51. Albain KS, Barlow WE, Shak S et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: A retrospective analysis of a randomised trial. Lancet Oncol 2010;11:55-65.
52. Tang G, Cuzick J, Wale C et al. Recurrence risk of node-negative and ERpositive early-stage breast cancer patients by combining recurrence score, pathologic, and clinical information: A meta-analysis approach [abstract 509]. Presented at the American Society of Clinical Oncology 2010 Annual Scientific Meeting, Chicago, IL, June 4-8, 2010.
53. Khatcheressian JL, Wolff AC, Smith TJ et al. American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. J Clin Oncol 2006;24:5091-5097.
54. Grunfeld E, Dhesy-Thind S, Levine M; Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. Clinical practice guidelines for the careandtreatment of breast cancer: Follow-up after treatment for breast cancer (summary of the 2005 update). CMAJ 2005;172:1319-1320.
55. Grunfeld E. Optimizing follow-up after breast cancer treatment. Curr Opin Obstet Gynecol 2009;21:92-96.